Views on the current price and future of Pfizer $PFE+0.9%?
The company is entering "the most important 18 months in Pfizer's history," CEO Bourla said in February. That's because the company plans to launch or expand the registration of 19 drugs over the next year and a half.
Those launches are expected to generate $20 billion in revenue by 2030, Bourla said. The group includes an RSV vaccine, elranatamab for multiple myeloma, ritlecitinib for alopecia areata and many other products.
Read more here 👇